
PTC Therapeutics: Regulatory Progress Report on Translarna (Ataluren) in Europe
PTC Therapeutics Announces EC Decision to Not Renew Authorization of Translarna™ for Duchenne Muscular Dystrophy PTC Therapeutics, Inc. (PTCT), a science-driven, global biopharmaceutical company, announced on March 28, 2025, that the European Commission (EC) has adopted the opinion of the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) not…